We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




African-Specific Molecular Taxonomy of Prostate Cancer Revealed

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: Histopathology of mucinous fibroplasia in prostate cancer (Photo courtesy of Cleveland Clinic)
Image: Histopathology of mucinous fibroplasia in prostate cancer (Photo courtesy of Cleveland Clinic)

Prostate cancer is characterized by considerable geo-ethnic disparity. African ancestry is a significant risk factor for the disease, with 2.7-fold higher mortality rates across sub-Saharan Africa than global averages, yet the genetic and non-genetic factors underlying this is not known.

Prostate cancer is characterized by a highly variable natural history and diverse clinical behaviors; it is not surprising that genome profiling has revealed extensive intra- and intratumor heterogeneity and complexity. The identification of oncogenic subtypes and actionable drug targets are moving prostate cancer management a step closer to the promise of precision medicine.

A large team of international scientists led by those at the University of Sydney, Camperdown, Australia) included in a study 183 treatment-naive patients with prostate cancer who were recruited from Australia (n = 53), Brazil (n = 7) and South Africa (n = 123). While matched for pathological grading, prostate-specific antigen levels are notably elevated within the African patients. DNA extracted from fresh tissue and matched blood underwent 2 × 150 bp sequencing on the NovaSeq instrument (Illumina, San Diego, CA, USA). The team performed whole-genome sequencing (WGS) to generate a large cancer genomics resource for sub-Saharan Africa that includes around two million somatic variants.

The scientists reported that findings specific to patients of African ancestry include an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and various cancer driver genes. They also describe a molecular taxonomy for prostate cancer differentiated by ancestry and defined as global mutational subtypes, while uncovering different evolutionary trajectories and mutational processes that suggest both common genetic and environmental factors contribute to the disparity between ethnicities. Significant African-ancestry-specific findings included an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and the driver genes NCOA2, STK19, DDX11L1, PCAT1 and SETBP1.

The authors concluded that their study suggests that larger genomic datasets of geo-ethnically diverse and ancestrally defined populations in a unified analysis will continue to identify rare and geographically restricted subtypes in prostate cancer and potentially other cancers. They demonstrated that ancestral and geographical attributes of patients could facilitate studies on cancer population genomics, an alternative to cancer personalized genomics, for a better scientific understanding of nature versus nurture. The study was published on August 31, 2022 in the journal Nature.

Related Links:
University of Sydney
Illumina 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.